Profound Medical (NASDAQ:PROF) Releases Earnings Results, Beats Expectations By $0.11 EPS

Profound Medical (NASDAQ:PROF) released its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.11, Zacks reports. The business had revenue of $4.18 million during the quarter, compared to analyst estimates of $5.92 million. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%.

Profound Medical Stock Performance

Shares of NASDAQ PROF opened at $7.29 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16. Profound Medical has a one year low of $5.63 and a one year high of $11.42. The business’s 50-day moving average price is $7.03 and its two-hundred day moving average price is $7.61. The company has a market capitalization of $218.99 million, a P/E ratio of -5.44 and a beta of 0.78.

Analyst Ratings Changes

Separately, Raymond James raised Profound Medical to a “strong-buy” rating in a research report on Saturday, November 9th.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.